Purpose: To describe the strategy used for large-scale ophthalmological monitoring in the
clinical development of the novel anticancer agent gefitinib (“Iressa”, ZD1839), an epidermal …

Purpose To describe the strategy used for large-scale ophthalmological monitoring in the
clinical development of the novel anticancer agent gefitinib ('Iressa', ZD1839), an epidermal …

Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It is
used for treating locally advanced or metastatic non-small cell lung carcinoma and is well …

Purpose:: Epidermal Growth Factor Inhibitor (EGF-I) medications are increasing popular in
the armament of anti cancer therapies. The purpose of this study was to better understand …

Purpose Epidermal growth factor receptor (EGFR) inhibitors and kinases are commonly
used in the treatment regimen of various solid tumors including non-small cell lung …

Background This phase I dose-escalating study investigated the tolerability and toxicity of
the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa' …

Background The objective of the five clinical studies presented in this article was to
investigate the single-dose pharmacokinetics of gefitinib (IRESSA®, ZD1839), an epidermal …

Purpose: Gefitinib (Iressa®) developed as an oral medication for non–small cell lung cancer.
This study was designed to verify a possibility of the prophylactic measure for after–cataract …

Purpose: Controversy exists regarding the safety of agents that systemically inhibits
epidermal growth factor receptor (EGFRi) in the ocular surface for oncologic patients. We …

The development of gefitinib ('Iressa', ZD1839) by targeting the EGFR tyrosine kinase is a
recent therapeutic highlight. We have reported that gefitinib is antiangiogenic in vitro, as well …